Insights from the SPARTAN Study
Ft. Drs. Jonathan Barratt and Shikha Wadhwani
The Role of Endothelin in IgAN
Donald Kohan, PhD, is an Emeritus Professor at the University of Utah Health with expertise in endothelin receptors, sodium transporters, and the renin-angiotensin-aldosterone system in chronic kidney disease.
In this episode, Professor Kohan provides an overview of the endothelin system and how it relates to the pathophysiology of chronic kidney disease and IgA nephropathy specifically.
Also find us on: Apple Podcasts Spotify Vimeo
Episode Summary
“Endothelin 1 is a really unusual molecule. It’s highly stable because it has two interchain disulfide bonds that resist degradation. It’s extremely potent having about 10-fold higher potency than any other known vasoactive factor.”
“Angiotensin and ET-1 cause their effects through different pathways.”
“Angiotensin stimulates transient calcium release, which causes more short-term contraction and other effects. While endothelin 1 stimulates more sustained calcium release, which then elicits longer lasting pathophysiologic effects.”
- Endothelin-1 acts via ETA receptors to cause vasoconstriction, fibrosis, cell proliferation and other effects that promote chronic kidney disease (04:41)
- The endothelin and renin-angiotensin systems interact, forming a vicious cycle that worsens kidney injury (06:15)
- In IgA nephropathy models, combined ETA + angiotensin receptor blockade with sparsentan reduced proteinuria and kidney injury more than angiotensin blockade alone (12:19)
Disclaimer: Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics. This podcast episode was recorded on June 24, 2024. Please always consult updated sources for the latest information, as information discussed may have changed since the recording date
MA-SP-24-0072
More Episodes Like This
From Podocyte to Patient: The Pathophysiology of FSGS
Ft. Dr. Tobias Huber
Introduction to FSGS
Ft. Dr. Howard Trachtman
MA-DS-24-0019 | May 2025